More than a decade after UCSF scientists discovered a way to target the once “undruggable” RAS protein, their work has led to an FDA-approved treatment that significantly extends survival for patients with metastatic pancreatic cancer.
A personalized mRNA vaccine tested at UC San Francisco has become the first to successfully prevent the return and spread of cancer in late-stage clinical trials. The results could signal a new era of vaccines to treat a range of cancers, says UCSF Professor of Medicine Adil Daud, MD, who led the university’s trial site.
Nine investigators and teams were awarded grants in support of cancer research projects in the spring 2026 cycle of the UCSF Resource Allocation Program (RAP). Learn about their research.
A UCSF-led study of more than 73,000 veterans shows a dramatic shift toward active surveillance for low-risk prostate cancer, reflecting efforts to reduce unnecessary treatment.